{'fraction_non_alphanumeric': 0.028073572120038724, 'fraction_numerical': 0.000968054211035818, 'mean_word_length': 5.847682119205298, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Development of a R$1 molecular test for rapid and direct detection of chikungunya virus from patient and mosquito samples

Introduction: The epidemic of Chikungunya virus (CHIKV) in the Americas has transformed a previously obscure mosquito-borne virus into a global public health concern. In regions where there is a simultaneous circulation of other arboviruses, such as dengue virus (DENV) and Zika virus (ZIKV), the clinical diagnosis of CHIKV infection becomes extremely difficult due to the similarities between their clinical manifestations and sometimes overlapping symptoms. Therefore, laboratory diagnosis is critical to correctly identify the etiological agent. Currently, the reverse transcriptase reaction followed by quantitative polymerase chain reaction (RT-qPCR) is the gold standard for molecular diagnostic of CHIKV in patient and mosquito samples. However, the technique presents several drawbacks, which limits the application for Point-of-care (POC) diagnostics, particularly in low and middle-income countries.